Canola-Mediterranean Diet Study in T2DM

September 17, 2018 updated by: Unity Health Toronto

Canola Enriched Mediterranean Type Weight Loss Diet in Type 2 Diabetes

The purpose of the study is to assess whether a Mediterranean-type weight-loss diet, enriched with canola oil, high in plant protein, and low in carbohydrates will produce blood sugar control, reduce coronary heart disease (CHD) risk factors and maximize weight loss, better than conventional higher carbohydrate diets in overweight diabetic patients.

Study Overview

Detailed Description

The investigators plan to assess the effects of increasing both canola oil and plant protein foods while reducing carbohydrate intake in the context of a Mediterranean type diet on weight loss, glycemic control and cardiovascular risk factors in type 2 diabetes.

Obesity rates in Western nations have shown a dramatic rise in the last 20 years and diabetes rates have doubled, a trend which is predicted to be repeated over the next 20 years. In Canada the predicted cost to the healthcare system in only 7 years will rise to $17 billion. Weight loss diets (such as Atkins, Eddies, South Beach and Zone) emphasizing carbohydrate restriction have become increasingly popular for the prevention and treatment of diabetes. As a result, lower carbohydrate diets are being selected by health conscious members of the general population including those with diabetes. Because such diets in effect promote a high intake of protein from animal sources, even in the presence of weight loss, serum cholesterol levels rise due to increased cholesterol and saturated fat intake; and a further rise in serum lipids is likely to occur in the long term when weight loss has ceased. On the other hand, lower carbohydrate dietary patterns that are higher in plant rather than animal fat and proteins have been associated with improved blood lipids and reduced risk of heart disease and type 2 diabetes.

The investigators have therefore planned a study in which a weight reducing low carbohydrate, Mediterranean type diet that is high in plant proteins and canola oil will be compared to a weight reducing high cereal fibre diet in a 3 month study. 150 overweight and obese participants with type 2 diabetes will be randomized to one of 2 treatments.

Study visits will be as follows: weeks -2, 0 (for randomization), 2, 4, 8, 10 and 12. Body measurements, blood pressure and blood samples will be taken at each visit except week 2. The week 2 visit will be mainly for reinforcement of dietary advice; also body weight will be measured and blood drawn for fast glucose and HbA1c. Diet records will be reviewed at all visits. 24 hour urine samples will be collected at week 0 and week 12.

On completion of the 12 week study, participants will be given the option of continuing on the same diet or trying the opposite diet for a further 12 weeks. Visits will be every 4 weeks for a total of 3 visit. Body measurements, blood pressure and blood samples will be taken during these visits as in the initial 12 week study.

Study Type

Interventional

Enrollment (Actual)

164

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Manitoba
      • Winnipeg, Manitoba, Canada, R3T 6C5
        • Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba
    • Ontario
      • Toronto, Ontario, Canada, M5C 2T2
        • Risk Factor Modification Centre, St. Michael's Hospital
    • Quebec
      • Quebec City, Quebec, Canada, G1V 4G2
        • Institute of Nutraceuticals and Functional Foods, Laval University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women with type 2 diabetes diagnosed for more than 6 months
  • BMI >27 (non-Asians); BMI >25 (Asians)
  • HbA1c between 6.5% and 8.5% at screening, and at the preparation visit before starting diet
  • on a stable prescribed dose of oral diabetes medication for at least 2 months
  • on a stable dose of lipid medication for at least 2 weeks, if prescribed
  • on a stable dose of blood pressure medication for at least 1 week, if prescribed
  • have a family physician
  • can keep written food records, with the use of a digital scale

Exclusion Criteria:

Individuals with the following characteristics/conditions will be excluded

  • on insulin
  • on steroids
  • on warfarin (Coumadin)
  • GI disease (gastroparesis, celiac, colitis, Crohn's disease, Inflammatory Bowel Syndrome)
  • history of cancer, except non-melanoma skin cancer (basal cell, squamous cell)
  • major cardiovascular event (stroke, myocardial infarction) in past 6 months
  • major surgery in past 6 months
  • major debilitating disorder
  • liver disease (AST or ALT> 3x the upper limit of normal) except non-alcoholic fatty liver (NAFL) disease or non-alcoholic steatohepatitis (NASH).
  • hepatitis B or C
  • renal failure (creatinine > 150 mmol/L)
  • serum triglycerides >4.5mmol/L
  • acute or chronic infections (bacterial or viral)
  • chronic inflammatory diseases (e.g. lupus, ulcerative colitis)
  • blood pressure >145/90, unless approved by their family physician
  • alcohol consumption >2 drinks/d
  • food allergies to wheat, canola, or other study food components
  • any condition determined by the investigators to make the subject unsuitable for the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: A canola oil enriched mediterranean diet
Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
Other Names:
  • A mediterranean weight-reducing diet emphasizing canola oil
  • Eco-Atkins diet
  • Low carbohydrate dietary portfolio
Active Comparator: A high wheat fiber diet
Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
Other Names:
  • DASH-type diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in HbA1c
Time Frame: Measured at weeks -2, 0, and then at weeks 8, 10 and 12
The baseline HbA1c will be the average HbA1c of weeks -2 and week 0. The end HbA1c will be the average HbA1c of weeks 8, 10 and 12. Change will be the difference between the end and baseline values
Measured at weeks -2, 0, and then at weeks 8, 10 and 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in body weight
Time Frame: baseline (week 0) and end (week 12)
baseline (week 0) and end (week 12)
blood glucose
Time Frame: At weeks 0, 2, 4, 8, 10 and 12
At weeks 0, 2, 4, 8, 10 and 12
Serum lipids: total cholesterol, LDL-chol, HDL-chol and Triglycerides
Time Frame: At weeks 0, 4, 8, 10 and 12
At weeks 0, 4, 8, 10 and 12
Blood pressure
Time Frame: At weeks 0, 4, 8, 10 and 12
At weeks 0, 4, 8, 10 and 12
24-hour Ambulatory blood pressure profile
Time Frame: At weeks -1 and 12
Measurement will be done using a non-invasive SpaceLabs 90217 Ambulatory BP monitor
At weeks -1 and 12
diet history
Time Frame: At weeks 0, 2, 4, 8, 10 and 12
7-day food records brought in at weeks 0, 2, 4, 8, 10 and 12 will be analyzed for macro and micro nutrient intakes.
At weeks 0, 2, 4, 8, 10 and 12
C-reactive protein
Time Frame: At weeks 0 and 12
At weeks 0 and 12
Cholesterol absorption
Time Frame: At weeks -1 and 12
This is an optional sub-study that will be carried out prior to the first and last weeks of the 12 week study. On day 1 (a Monday) of the week -1 and last weeks of the study after an overnight 12hr fast, blood will be drawn and participants will be asked to ingest 75mg of the stable carbon isotope [3, 4-13C] cholesterol dissolved in 5g of margarine and spread on half of an English muffin. Subsequent blood draws will be taken after an overnight 12hr fast, at 48 h (a Wednesday) and 72 h (a Thursday) after ingestion of the labeled cholesterol.
At weeks -1 and 12
change in LDL particle size
Time Frame: Weeks 0 and 12
LDL particle size at weeks 0 and 12 will be determined by assessing their electrophoretic characteristics obtained by non-denaturing polyacrylamide gradient (2-16%) gel electrophoresis of serum
Weeks 0 and 12
urinary analyses
Time Frame: week 0 and week 12
24 hr urine samples will be analyzed for creatinine, urea, C-peptide, minerals, electrolytes and other dietary biomarkers
week 0 and week 12

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Satiety
Time Frame: at weeks 0, 2, 4, 8, 10 and 12
Using a 9-point bipolar semantic scale where -4 is extremely hungry, 0 is neutral and +4 is uncomfortably full, participants will rate their overall feeling of satiety for the previous week.
at weeks 0, 2, 4, 8, 10 and 12
Taste (palatability) of the study diets, breads and other supplements given
Time Frame: At weeks 2, 4, 8, 10 and 12
Using a scale of 1 (strongly dislike) to 10 (like very much), participants will rate the taste (palatability) of the study diet and supplements including study breads, vegan 'meats' and egg products.
At weeks 2, 4, 8, 10 and 12
The Medical Outcomes Study 36-Item Short Form Questionnaire (SF-36)
Time Frame: At weeks 0 and 12
Survey on quality of life
At weeks 0 and 12
Genetic whole genome testing
Time Frame: Week 0 or any other time point
One time sample collection of buffy coat (from white cells) for future study on gene, diet and chronic disease relationship.
Week 0 or any other time point
complete blood count (CBC)
Time Frame: Week 0 and week 12
Health check at start and end of study
Week 0 and week 12
Renal function test
Time Frame: week 0 and week 12
Health check at start and end of study
week 0 and week 12
Liver function test
Time Frame: week 0 and week 12
Health check at start and end of study
week 0 and week 12
Prostatic specific antigen (PSA)
Time Frame: week 0 and week 12
Male participants will undergo this test.
week 0 and week 12
sustainability of diet
Time Frame: week 10 and week 12
using a scale of 1 (study diet will be very difficult to sustain) to 10 (study diet will be very easy to sustain) participants will assess how sustainable their assigned diet will be on a long-term basis.
week 10 and week 12
Testosterone level
Time Frame: week 0 and week 12
Male participants will undergo this test
week 0 and week 12
Estradiol level
Time Frame: week 0 and week 12
Female participants will undergo this test
week 0 and week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Cyril Kendall, PhD, University of Toronto
  • Study Director: Vladimir Vuksan, PhD, Unity Health Toronto

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2014

Primary Completion (Actual)

December 14, 2016

Study Completion (Actual)

March 13, 2017

Study Registration Dates

First Submitted

September 5, 2014

First Submitted That Met QC Criteria

September 17, 2014

First Posted (Estimate)

September 19, 2014

Study Record Updates

Last Update Posted (Actual)

September 18, 2018

Last Update Submitted That Met QC Criteria

September 17, 2018

Last Verified

September 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on A canola oil enriched mediterranean diet

Subscribe